689 related articles for article (PubMed ID: 34925359)
41. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
Chu L; Vrbicky K; Montefiori D; Huang W; Nestorova B; Chang Y; Carfi A; Edwards DK; Oestreicher J; Legault H; Dutko FJ; Girard B; Pajon R; Miller JM; Das R; Leav B; McPhee R
Nat Med; 2022 May; 28(5):1042-1049. PubMed ID: 35241844
[TBL] [Abstract][Full Text] [Related]
42. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
43. mRNA Covid-19 vaccines in pregnancy: A systematic review.
Pratama NR; Wafa IA; Budi DS; Putra M; Wardhana MP; Wungu CDK
PLoS One; 2022; 17(2):e0261350. PubMed ID: 35108277
[TBL] [Abstract][Full Text] [Related]
44. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
Reyes-Leiva D; López-Contreras J; Moga E; Pla-Juncà F; Lynton-Pons E; Rojas-Garcia R; Turon-Sans J; Querol L; Olive M; Álvarez-Velasco R; Caballero-Ávila M; Carbayo Á; Vesperinas-Castro A; Domingo P; Illa I; Gallardo E; Cortés-Vicente E
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35728947
[TBL] [Abstract][Full Text] [Related]
45. Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.
Santos-Araújo C; Mota Veiga P; Santos MJ; Santos L; Romãozinho C; Silva M; Lucas C; Duarte ML; Haarhaus M; Haase M; Macário F
Nephrol Dial Transplant; 2022 Jan; 37(2):375-381. PubMed ID: 34634116
[TBL] [Abstract][Full Text] [Related]
46. Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review.
Akyol M; Çevik E; Ucku D; Tanrıöver C; Afşar B; Kanbay A; Covic A; Ortiz A; Basile C; Kanbay M
Tuberk Toraks; 2021 Dec; 69(4):547-560. PubMed ID: 34957748
[TBL] [Abstract][Full Text] [Related]
47. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
48. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
[TBL] [Abstract][Full Text] [Related]
49. Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity.
Choi MJ; Heo JY; Seo YB; Yoon YK; Sohn JW; Noh JY; Cheong HJ; Kim WJ; Choi JY; Kim HJ; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
Front Immunol; 2022; 13():1035441. PubMed ID: 36700198
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM
JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765
[TBL] [Abstract][Full Text] [Related]
51. Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers.
Prins MLM; Prins C; de Vries JJC; Visser LG; Roukens AHE
Virus Res; 2023 Sep; 334():199175. PubMed ID: 37473964
[TBL] [Abstract][Full Text] [Related]
52. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
[TBL] [Abstract][Full Text] [Related]
53. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.
Duni A; Markopoulos GS; Mallioras I; Pappas H; Pappas E; Koutlas V; Tzalavra E; Baxevanos G; Priska S; Gartzonika K; Mitsis M; Dounousi E
Front Immunol; 2021; 12():760249. PubMed ID: 34925330
[TBL] [Abstract][Full Text] [Related]
54. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.
Piros ÉA; Cseprekál O; Görög A; Hidvégi B; Medvecz M; Szabó Z; Olajos F; Barabás E; Galajda N; Miheller P; Holló P
Dermatol Ther; 2022 May; 35(5):e15408. PubMed ID: 35218276
[TBL] [Abstract][Full Text] [Related]
55. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.
Bakasis AD; Bitzogli K; Mouziouras D; Pouliakis A; Roumpoutsou M; Goules AV; Androutsakos T
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215801
[TBL] [Abstract][Full Text] [Related]
56. Antibody responses to inactivated SARS-CoV-2 vaccine in peritoneal dialysis patients.
Murt A; Altiparmak MR; Ozbey D; Yalin SF; Sert Yadigar S; Karaali R; Kocazeybek B; Saltoglu N; Pekpak M; Ataman MR
Semin Dial; 2022 May; 35(3):264-268. PubMed ID: 34989454
[TBL] [Abstract][Full Text] [Related]
57. "COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment".
Munavalli GG; Guthridge R; Knutsen-Larson S; Brodsky A; Matthew E; Landau M
Arch Dermatol Res; 2022 Jan; 314(1):1-15. PubMed ID: 33559733
[TBL] [Abstract][Full Text] [Related]
58. Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis.
Yoshifuji A; Toda M; Ryuzaki M; Kikuchi K; Kawai T; Sakai K; Oyama E; Koinuma M; Katayama K; Uehara Y; Ohmagari N; Kanno Y; Kon H; Shinoda T; Takano Y; Tanaka J; Hora K; Nakazawa Y; Hasegawa N; Hanafusa N; Hinoshita F; Morikane K; Wakino S; Nakamoto H; Takemoto Y
Ren Replace Ther; 2022; 8(1):39. PubMed ID: 35999867
[TBL] [Abstract][Full Text] [Related]
59. Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan.
Kang CM; Lee NY; Lin CH; Hsu YS; Chang YC; Chung MY; Lee YF; Tseng WP; Wu JL; Chen SY; Lu MC; Ko WC; Lee PI; Hsueh PR
J Clin Virol; 2022 Jun; 150-151():105156. PubMed ID: 35413588
[TBL] [Abstract][Full Text] [Related]
60. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
